TWI887352B - 具有ｂｒｄ４蛋白質分解誘導作用的磺醯胺或亞磺醯胺化合物及其作為醫藥的用途 - Google Patents

具有ｂｒｄ４蛋白質分解誘導作用的磺醯胺或亞磺醯胺化合物及其作為醫藥的用途 Download PDF

Info

Publication number
TWI887352B
TWI887352B TW110104483A TW110104483A TWI887352B TW I887352 B TWI887352 B TW I887352B TW 110104483 A TW110104483 A TW 110104483A TW 110104483 A TW110104483 A TW 110104483A TW I887352 B TWI887352 B TW I887352B
Authority
TW
Taiwan
Prior art keywords
group
cyano
substituted
halogen atom
methyl
Prior art date
Application number
TW110104483A
Other languages
English (en)
Chinese (zh)
Other versions
TW202140498A (zh
Inventor
大場清美
丹羽靖哉
松平鉄二
濵田真以子
山崎竜太
伊吹達也
Original Assignee
日商田邊三菱製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=77199607&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI887352(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 日商田邊三菱製藥股份有限公司 filed Critical 日商田邊三菱製藥股份有限公司
Publication of TW202140498A publication Critical patent/TW202140498A/zh
Application granted granted Critical
Publication of TWI887352B publication Critical patent/TWI887352B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW110104483A 2020-02-06 2021-02-05 具有ｂｒｄ４蛋白質分解誘導作用的磺醯胺或亞磺醯胺化合物及其作為醫藥的用途 TWI887352B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020019227 2020-02-06
JP2020-019227 2020-02-06

Publications (2)

Publication Number Publication Date
TW202140498A TW202140498A (zh) 2021-11-01
TWI887352B true TWI887352B (zh) 2025-06-21

Family

ID=77199607

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110104483A TWI887352B (zh) 2020-02-06 2021-02-05 具有ｂｒｄ４蛋白質分解誘導作用的磺醯胺或亞磺醯胺化合物及其作為醫藥的用途

Country Status (14)

Country Link
US (3) US12102641B2 (https=)
EP (1) EP4105220A4 (https=)
JP (3) JP7419406B2 (https=)
KR (1) KR20220139912A (https=)
CN (1) CN115087658B (https=)
AR (1) AR121275A1 (https=)
AU (1) AU2021215623A1 (https=)
BR (1) BR112022014889A2 (https=)
CA (1) CA3168824C (https=)
IL (1) IL295041A (https=)
MX (1) MX2022009700A (https=)
TW (1) TWI887352B (https=)
WO (1) WO2021157684A1 (https=)
ZA (1) ZA202209896B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7419406B2 (ja) 2020-02-06 2024-01-22 田辺三菱製薬株式会社 Ｂｒｄ４蛋白質分解誘導作用を有するスルホンアミドあるいはスルフィンアミド化合物及びその医薬としての用途
JP2022123408A (ja) * 2021-02-12 2022-08-24 株式会社三洋物産 遊技機
JP2022123894A (ja) * 2021-02-12 2022-08-25 株式会社三洋物産 遊技機
JP2022123407A (ja) * 2021-02-12 2022-08-24 株式会社三洋物産 遊技機
JP2022123893A (ja) * 2021-02-12 2022-08-25 株式会社三洋物産 遊技機
JP7852736B2 (ja) * 2022-10-28 2026-04-28 株式会社村田製作所 電子部品および電子部品の実装構造
WO2024251876A1 (en) * 2023-06-07 2024-12-12 KRæFTENS BEKæMPELSE PROTACs AND HyT-PD MOLECULES FOR TARGETED PROTEIN DEGRADATION OF DCAF15 AND THEIR USE IN THE TREATMENT OF AMYLOIDOSIS
CN118359621B (zh) * 2024-04-16 2025-05-16 上海陶术生物科技股份有限公司 加利司伟及加利司伟中间体的制备方法和相应的加利司伟中间体
CN120865239B (zh) * 2025-09-25 2025-12-12 深圳大学 基于苯并咪唑融合共价弹头的降解剂及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018188660A1 (zh) * 2017-04-13 2018-10-18 中国科学院上海药物研究所 一种brd4抑制剂及其制备和应用
WO2019052519A1 (zh) * 2017-09-14 2019-03-21 成都海创药业有限公司 一种brd4抑制剂
WO2020009176A1 (ja) * 2018-07-04 2020-01-09 田辺三菱製薬株式会社 Ｂｅｔ蛋白質分解誘導作用を有するアミド化合物及びその医薬としての用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959361A (en) 1987-12-18 1990-09-25 Hoffmann-La Roche Inc. Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists
EP0638560A4 (en) 1991-10-11 1995-03-29 Yoshitomi Pharmaceutical MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *.
WO1994006802A1 (fr) * 1992-09-18 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Compose de thienodiazepine et son utilisation medicinale
JP2801500B2 (ja) 1993-07-02 1998-09-21 株式会社トクヤマ Ｎ−アルコキシカルボニルアミノ酸の製造方法
CN1109037C (zh) 1996-09-13 2003-05-21 三菱制药株式会社 噻吩并－三唑并二氮杂䓬化合物及其医药用途
WO2006129623A1 (ja) 2005-05-30 2006-12-07 Mitsubishi Tanabe Pharma Corporation チエノトリアゾロジアゼピン化合物及びその医薬としての用途
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2017197056A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
EP3723757A4 (en) 2017-12-14 2021-08-18 Dana-Farber Cancer Institute, Inc. SMALL MOLECULE TYPE DEGRADATION AGENTS RECRUITING DCAF15
US11629152B2 (en) * 2018-03-30 2023-04-18 Kyowa Kirin Co., Ltd. Compound with anticancer activity
JP7140273B2 (ja) 2019-04-09 2022-09-21 株式会社村田製作所 電池
JP7419406B2 (ja) * 2020-02-06 2024-01-22 田辺三菱製薬株式会社 Ｂｒｄ４蛋白質分解誘導作用を有するスルホンアミドあるいはスルフィンアミド化合物及びその医薬としての用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018188660A1 (zh) * 2017-04-13 2018-10-18 中国科学院上海药物研究所 一种brd4抑制剂及其制备和应用
WO2019052519A1 (zh) * 2017-09-14 2019-03-21 成都海创药业有限公司 一种brd4抑制剂
WO2020009176A1 (ja) * 2018-07-04 2020-01-09 田辺三菱製薬株式会社 Ｂｅｔ蛋白質分解誘導作用を有するアミド化合物及びその医薬としての用途

Also Published As

Publication number Publication date
KR20220139912A (ko) 2022-10-17
US20230146717A1 (en) 2023-05-11
ZA202209896B (en) 2025-12-17
MX2022009700A (es) 2022-09-07
US12102641B2 (en) 2024-10-01
WO2021157684A1 (ja) 2021-08-12
EP4105220A4 (en) 2024-02-21
IL295041A (en) 2022-09-01
AU2021215623A1 (en) 2022-08-25
CA3168824C (en) 2024-10-22
TW202140498A (zh) 2021-11-01
US20230364105A1 (en) 2023-11-16
AR121275A1 (es) 2022-05-04
CN115087658B (zh) 2025-02-28
JPWO2021157684A1 (https=) 2021-08-12
JP2024041888A (ja) 2024-03-27
JP7419406B2 (ja) 2024-01-22
CA3168824A1 (en) 2021-08-12
EP4105220A1 (en) 2022-12-21
JP2025122015A (ja) 2025-08-20
CN115087658A (zh) 2022-09-20
US11890288B2 (en) 2024-02-06
JP7681737B2 (ja) 2025-05-22
BR112022014889A2 (pt) 2022-09-20
US20240390387A1 (en) 2024-11-28

Similar Documents

Publication Publication Date Title
TWI887352B (zh) 具有ｂｒｄ４蛋白質分解誘導作用的磺醯胺或亞磺醯胺化合物及其作為醫藥的用途
TW202019946A (zh) 具有ｂｅｔ蛋白質分解誘導作用的醯胺化合物及其作為醫藥的用途
CN110267945A (zh) 氰基取代的吲哚化合物及其作为lsd1抑制剂的用途
CN112028870B (zh) 一种具有苄氧基芳环结构的化合物，其制备方法和用途
CN114409656B (zh) Pim激酶抑制剂
CN109956898A (zh) 免疫调节剂及其制法与医药上的用途
EP2760840A1 (en) Quinolinone carboxamide inhibitors of endothelial lipase
EP2760828A1 (en) Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
EP2760830A1 (en) Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
EP2760829A1 (en) Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
WO2013151923A1 (en) Pyrimidinone carboxamides as inhibitors of endothelial lipase
CN110483366B (zh) 吲哚类化合物及其制备方法、药物组合物和用途
JP7614145B2 (ja) Ｂｒｄ４蛋白質分解誘導剤を含む医薬
CN113966324A (zh) Notch信号传导途径抑制剂及其在癌症治疗的用途
CN115715286A (zh) 用于癌症治疗的bcl-2家族蛋白调节化合物
CN105358544A (zh) 杂环化合物
RU2830112C1 (ru) Соединение сульфонамида или сульфинамида, обладающее эффектом индуцирования деградации белка brd4, и его применение в медицине
CN116348114A (zh) 硫代苯并咪唑衍生物或其药学上可接受的盐及其用途
CN115724784A (zh) 作为p53调节剂和/或hdac抑制剂的化合物
KR102939621B1 (ko) 헤테로비시클릭 화합물 및 그를 포함하는 약제학적 조성물
HK40080729A (en) Sulfonamide or sulfinamide compound having effect of inducing brd4 protein degradation and pharmaceutical use thereof
WO2025162115A1 (zh) 一种杂环化合物及其制药用途
WO2026007898A1 (zh) 含苯乙氧基亚烷基胺结构的异吲哚啉化合物、其药物组合物及应用